Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck

KIEV, Ukraine–(BUSINESS WIRE)–Enamine Ltd. a provider of integrated drug discovery services empowered
by the world’s largest collections of building blocks and screening
compounds, and H. Lundbeck A/S (Lundbeck), the global pharmaceutical
company involved in the research of new drugs for the treatment of
disorders in the central nervous system, today announced the expansion
of their research collaboration. Enamine will support Lundbeck’s
in-house discovery chemistry competencies with three principal assets
enabling Lundbeck to optimally identify and develop hit series in its
multiple research programs.

• A large diverse library of 100,000 new screening compounds for hit
  finding activities on numerous therapeutic targets.
• Enamine’s make-on-demand REAL compounds (Nature, 2019, Vol. 566, p.
  224–229) for efficient access to billions of novel chemical compounds.
• An increased dedicated team of Enamine FTE chemists to effectively
  support Lundbeck on all hit related follow-up activities backed by
  immediate access to over 170,000 building blocks in Enamine’s
  inventory.

Dr. Paul Kilburn, Director and Head of Medicinal Chemistry at
Lundbeck said: “Enamine’s REAL Database is allowing us to
expedite our hit explosion programs at unmatched speed and synthesis
success. We look forward to the results of our HTS campaigns and to
continue receiving highly valuable compounds exclusively synthesized for
us.”

Michael Bossert, Head of Strategic Alliances at Enamine, commented:
“We are delighted to extend our collaboration with Lundbeck, with whom
we have a strong historical relationship. This reflects the
high-performance level already achieved and a confidence mutually
shared, which is most gratifying.”

END

About Enamine www.enamine.net

Enamine is a science-driven chemicals company and provider of the
world’s largest stock collections of building blocks and screening
compounds. The company’s medicinal chemistry capabilities are enhanced
with on-site HTS, ADMET-DMPK and early preclinical studies, to provide
an easily customizable integrated service package.

About Lundbeck www.lundbeck.com

Lundbeck is a global pharmaceutical company highly committed to
improving the quality of life of people living with psychiatric and
neurological disorders. For this purpose, Lundbeck is engaged in the
research, development, production, marketing and sale of pharmaceuticals
across the world. The company’s products are targeted at the disease
areas depression, schizophrenia, Parkinson’s disease and Alzheimer’s
disease.

Contacts

Media
Sarah Jeffery
E: [email protected]

Enamine
Ltd.
Michael Bossert
E: [email protected]